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Background-—Inactivation of Shox2, a member of the short-stature homeobox gene family, leads to defective development of
multiple organs and embryonic lethality as a result of cardiovascular defects, including bradycardia and severe hypoplastic
sinoatrial node (SAN) and sinus valves, in mice. It has been demonstrated that Shox2 regulates a genetic network through the
repression of Nkx2.5 to maintain the fate of the SAN cells. However, the functional mechanism of Shox2 protein as a
transcriptional repressor on Nkx2.5 expression remains completely unknown.
Methods and Results-—A speciﬁc interaction between the B56d regulatory subunit of PP2A and Shox2a, the isoform that is
expressed in the developing heart, was demonstrated by yeast 2-hybrid screen and coimmunoprecipitation. Western blotting and
immunohistochemical assays further conﬁrmed the presence of phosphorylated Shox2a (p-Shox2a) in cell culture as well as in the
developing mouse and human SAN. Site-directed mutagenesis and in vitro kinase assays identiﬁed Ser92 and Ser110 as true
phosphorylation sites and substrates of extracellular signal-regulated kinase 1 and 2. Despite that Shox2a and its phosphorylation
mutants possessed similar transcriptional repressive activities in cell cultures when fused with Gal4 protein, the mutant forms
exhibited a compromised repressive effect on the activity of the mouse Nkx2.5 promoter in cell cultures, indicating that
phosphorylation is required for Shox2a to repress Nkx2.5 expression speciﬁcally. Transgenic expression of Shox2a, but not Shox2a-
S92AS110A, mutant in the developing heart resulted in down-regulation of Nkx2.5 in wild-type mice and rescued the SAN defects
in the Shox2 mutant background. Last, we demonstrated that elimination of both phosphorylation sites on Shox2a did not alter its
nuclear location and dimerization, but depleted its capability to bind to the consensus sequences within the Nkx2.5 promoter
region.
Conclusions-—Our studies reveal that phosphorylation is essential for Shox2a to repress Nkx2.5 expression during SAN
development and differentiation. (J Am Heart Assoc. 2014;3:e000796 doi: 10.1161/JAHA.114.000796)
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H
eart defects are among the most common birth defects
and are the leading cause of birth defect-related death.
1
The sinoatrial node (SAN), a specialized group of cells at the
junction of the superior vena cava and right atrium, functions
as the primary cardiac pacemaker that controls the rhythm of
the heartbeat. Sinus node dysfunctions cause cardiac defects,
especially bradycardia, arrhythmias, and, in severe cases, lead
to cardiac arrest, sinoatrial exit block, and sudden death.
2,3
Although extensive studies have been conducted to describe
the morphology, cellular components, and electrophysiolog-
ical properties, structure of the normal and diseased pace-
maker tissues, genetic regulation, and molecular mechanisms
underlying SAN development and pathogenesis remain elu-
sive. Elucidation of genetic mechanisms that control SAN
development will shed light on the therapeutic intervention of
both congenital and acquired pacemaker defects.
Several members of the homeobox and T-box gene families
have been demonstrated to be key regulators in SAN
formation and function.
4,5 Among them is the paired-related
homeodomain transcription factor, Shox2, 1 of the 2 members
in the short-stature homeobox gene family. During embryonic
heart development, Shox2 is expressed in the sinus venosus
region, including the SAN and the sinus valves.
6,7 Similar
expression pattern of SHOX2 was also reported in the human
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8,9 Shox2 null mutation causes embryonic
lethality between embryonic day 11.5 (E11.5) and E12.5 as a
result of cardiovascular (CV) defects, including severe hypo-
plastic SAN and bradycardia associated with down-regulation
of the SAN-speciﬁc marker genes, Tbx3 and Hcn4, and ectopic
expression of Nkx2.5, Cx40, Cx43, and Nppa within the SAN
region.
6,7 Gene expression analysis indicates that Shox2 and
Nkx2.5 are expressed in a mutually exclusive manner from the
earliest stages of the venous pole and the SAN formation until
at least E15.5.
4,6,7 Nkx2.5 overexpression produced the same
SAN and sinus valve phenotypes as that observed in Shox2
 / 
hearts, suggesting that Nkx2.5 activity is detrimental to SAN
development and that Shox2 plays an essential role in SAN
development through repression of Nkx2.5.
4,10 However, the
functional mechanism of Shox2 protein as a transcriptional
repressor on Nkx2.5 expression is unknown.
Post-translational modiﬁcations, including protein phos-
phorylation, regulate activities and functions of transcription
factors. Protein phosphorylation can rapidly regulate the
activity of many eukaryotic transcription factors during
development and physiological processes at different levels,
such as protein stability, cellular localization, protein-protein
interaction and oligomerization, DNA-binding activity, and
transcriptional potential.
11 For example, SHOX protein, the
paralogous of human SHOX2, whose mutations or deletions
have been associated with syndromic short stature, such as
Turner syndrome, L eri-Weill dyschondrosteosis, and Langer
mesomelic dysplasia in humans, was found to be phosphor-
ylated in vivo on several serine residues.
12 The replacement of
Ser106, the major phosphorylation site, with Ala does not
alter SHOX nuclear translocation and DNA-binding capability,
but completely abolishes the transcriptional activity of the
protein.
12
In this study, we attempted to address the functional
mechanism underlying Nkx2.5 repression by Shox2a, the
isoform that is expressed in the developing heart.
6 We
present in vitro and in vivo evidence demonstrating that
phosphorylation of Shox2a is required for its speciﬁc binding
to the Nkx2.5 promoter and its function to repress Nkx2.5
expression.
Methods
Animal and Human Samples
All animal experiments were approved by the Tulane Univer-
sity Institutional Animal Care and Use Committee (New
Orleans, LA) and were conducted in strict accordance with the
Guide for Care and Use of Laboratory Animals of the National
Institutes of Health (NIH). Generation of transgenic (Tg) mice
are described in detail in the following section. Mouse
embryos (total of approximately 80) were harvested from
timed pregnant females and ﬁxed in 4% paraformaldehyde
(PFA) in PBS at 4°C overnight. Surgically and medically
terminated human embryos (N=4) were provided by the
Hospital for Women and Children of Fujian Province (Fuzhou,
China), with the permission of the Ethics Committee of Fujian
Normal University (Fuzhou, China). Samples were then
dehydrated through a graded ethanol series, embedded, and
processed for parafﬁn serial sections at 7 lm, and sections
were subjected to immunohistochemistry (IHC).
Generation of pMes-Shox2a-S92A/S110A Tg Mice
Similar to the generation of pMes-Shox2a Tg mice reported
on previously,
10 Shox2a-S92A/S110A (also named Shox2a-
DM) DNA was ampliﬁed by polymerase chain reaction (PCR)
and ligated into the pMES-STOP vector. Tg DNA fragment
containing the chicken b-actin/cytomegalovirus (CMV)
enhancer promoter, the loxP ﬂanked transcriptional STOP
cassette, and Shox2a-S92A/S110A sequences, followed by
the Ires22-Egfp sequence and a rabbit b-globin poly(A) tail,
was released by BciVI and used for pronuclear injection at the
Tulane Transgenic/Knockout facility. Tg mice with tissue-
speciﬁc transgene expression (Shox2a
CO or Shox2a-DM
CO)
were obtained by crossing the pMes-Shox2a or pMes-Shox2a-
DM lines with the cTnt-Cre Tg line, which expresses Cre
recombinase in the cardiac tissue, including the SAN.
10 Tg
mice were identiﬁed by a PCR-based genotyping, and binary
transgenic embryos were identiﬁed by cardiac-speciﬁc
expression of enhanced green ﬂuorescent protein (EGFP)
under UV light and further conﬁrmed by PCR genotyping.
Yeast Two-Hybrid Screening Shox2a Interacts
With the B56d Regulatory Subunit of PP2A
MatchmarkerGAL4 Two-Hybrid System 3 (Clontech Laborato-
ries, Mountain View, CA) was used for screening. The bait
plasmid contains the Shox2a coding sequences without its
transactivation domain (C-terminal 19 amino acids) in
pGBKT7. For library screening, bail plasmid was transformed
into yeast strain AH109. The transformed yeast was cultured
and mated with the Matchmaker pretransformed 11-day
mEmbryo cDNA library (Catalog No.: 638868; Clontech
Laboratories). Yeast colonies were selected on yeast nitrogen
base medium that contains 2% glucose and lacks adenine,
histidine, leucine, and trytophan. Approximately 1.15910
7
cotransformants were obtained. Colonies were picked and
checked for beta-galactosidase (b-Gal) production using a
ﬁlter assay with 5-bromo-4-chloro-3-indolyl-b-D-galactopyr-
anoside. Plasmids were isolated from positive clones, and a
second round of interaction screening was performed to
conﬁrm the interactions. The inserts from positive clones
were sequenced.
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HProtein Coimmunoprecipitation Assay
The Z-precipitation kit from Innovative BioSolutions LLC
(Frederick, MD) was used for protein-protein interaction
assays. Shox2a or Shox2a-S92A/S110A was cloned in frame
to the Z-tag within the MCS of the vector, following by
transfection in HEK-293T cells. Shox2a or its phosphorylation
mutant proteins were expressed in fusion to the Z-tag and
interacted with potential cotransfected partners. Cells were
lysed in binding buffer (50 mmol/L of Tris-HCl [pH 8.0],
150 mmol/L ofNaCl,5 mmol/LofEDTA,1%NonidetP40,and
proteaseinhibitorcocktail)andthelysateswereincubatedwith
sepharosebeadsfor2 hourstoovernightat4°C.Afterwashing
with binding buffer, bound proteins were released with protein
loading buffer (Catalog No.: 928-40004; LI-COR Biosciences,
Lincoln, NE) and subjected to Western blotting analysis.
Cell Culture, Transfection, and Luciferase Assay
HEK-293T cells were cultured at 37°C in DMEM containing
high glucose, supplemented with 10% FCS and antibiotics. To
generate constructs expressing fusion proteins with the GAL4
DNA-binding domain, we subcloned the following DNA
fragments into the pBXG1 vector that contains the GAL4
DNA-binding domain under the control of the SV40 enhancer/
promoter: full-length mouse Shox2a, Shox2a-S92A, Shox2a-
S110A, and Shox2a-S92A/S110A. To test potential transcription
activities, the resultant expression vectors were cotransfected
into cells with L8G5-Luc reporter plasmid that contains 8 LexA
operators with 5 GAL4-binding sites upstream of a TATA box
and the luciferase (Luc) reporter gene. The CMV-b-Gal plasmid
was included as an internal control for transfection efﬁciency.
Forty-eight hours after transfection using Lipofectamine
TM
2000 Reagent (Invitrogen, Carlsbad, CA), according to the
manufacturer’s instruction, luciferase activities were deter-
mined and normalized to b-Gal activity. HL-1 cells were
maintained at 37°C in Claycomb medium (Catalog No.:
51800C; Sigma-Aldrich, St. Louis, MO) supplemented with
10% FBS, 0.1 mmol/L of norepinephrine, 2 mmol/L of L-
glutamine, and antibiotics. Cells were split in two once they
reached conﬂuence on gelatin/ﬁbronectin-coated plates. To
measure repressive activities of Shox2a or its phosphorylation
mutants on the Nkx2.5 promoter, the Shox2a and its mutant
expression vectors were cotransfected into cells with the
Nkx2.5-Luc reporter plasmid that harbors a 3.3-kb mouse
Nkx2.5 upstream fragment linked to the luciferase reporter
gene.
6 The pRL-SV40 plasmid was included as an internal
control for transfection efﬁciency. Transfection on HL-1 cells
was performed using PolyJet
TM In Vitro DNA Transfection
Reagent (SignaGen Laboratories, Gaithersburg, MD), accord-
ing to the manufacturer’s instruction. Forty-eight hours after
transfection, ﬁreﬂy luciferase activities were determined and
normalized to Renilla luciferase activity. In order to test the
effect of PP2A inhibitor or extracellular signal-regulated
kinase (Erk)1/2 inhibitor on Shox2a transcription activities,
cotransfected cells were treated with different concentration
of okadaic acid (Catalog No.: O7885-50UG; Sigma-Aldrich) or
U0126 (Catalog No.: 9903; Cell Signaling Technology, Dan-
vers, MA) 24 hours after transfection. Reporter assays were
carried out after 24 hours in culture.
In Vitro Kinase Assay
The Shox2a, Shox2a-92a, or Shox2a-110A construct was
transfected into HEK-293T cells using Lipofectamine 2000
Reagent (Invitrogen). Forty-eight hours after transfection, cells
were harvested, lysed, and subjected to immunoprecipitation.
Immunoprecipitated proteins were suspended in PBS and
incubated with either cell division control protein kinase 2
(Cdc2) (NEB, P6020S) or Erk2 (NEB, P6080S) at 30°C for
30 minutes, following the manufacturer’s instruction. Protein
samples were released with protein-loading buffer (Catalog
No.: 928-40004; LI-COR Biosciences) and subjected to
Western blotting analysis.
Immunostaining
Customized polyclonal antibodies against phosphorylated
Ser92 and Ser110 of Shox2a were designed and generated
by GenScript (Piscataway, NJ), respectively. IHC staining was
performed by standard procedures. All samples were ﬁxed in
4% PFA, embedded in parafﬁn, and sectioned at 7-lm
thickness. Sections, after rehydration, were treated with
0.3% H2O2 in PBS for 20 minutes to inhibit endogenous
peroxidase, followed by incubation with 0.01 mol/L of citric
buffer (pH 6.0) at 97°C for 20 minutes for antigen retrieval.
Samples were then incubated at 4°C overnight with the
following primary antibodies in PBS/Tween-20 with 1% BSA:
1/100 S92 phosphorylation-speciﬁc Shox2a antibody, 1/
1000 S110 phosphorylation-speciﬁc Shox2a antibody, 1/
4000 anti-NK2 transcription factor-related locus 5 (Nkx2.5;
Catalog No.: sc-8697; Santa Cruz Biotechnology, Santa Cruz,
CA). Samples were then rinsed with PBS (29) and PBS-Tween-
20 (19) before being incubated with 1 of the following biotin-
conjugated secondary antibodies, including biotinylated
anti-rabbit immunoglobulin G (IgG; Vector BA-1000), biotiny-
lated anti-rat IgG (Vector BA-9401), and biotinylated anti-goat
IgG (Vector BA-9500) and 1/66 serum in PBS/Tween-20 for
40 minutes. Thereafter, all slides were rinsed with PBS 3
times and incubated with 1/400 Streptavidin-HRP (Invitrogen
434323) in PBS for 10 minutes, then were visualized with
incubated with 3,3’-diaminobenzidine (DAB) substrate (DAB
substrate Kit; Catalog No.: 00-2014; Invitrogen).
For immunocytochemistry (ICC), transfected cells were
ﬁxed with 4% PFA in PBS for 10 minutes, washed with PBS,
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Hand treated with 1% Triton X-100 for 15 minutes. Cells were
incubated with rat monoclonal antibodies against hemagglu-
tinin (HA; Catalog No.: 12158167001; Roche Diagnostics,
Indianapolis, IN), and signals were revealed with a mouse
ﬂuorescein isothiocyanate–conjugated anti-HA monoclonal
antibody (green), together with 4’,6-diamidino-2-phenylindole
(DAPI) counterstaining.
TaqMan Real-Time PCR
Hearts from newborn (P0) pups were subjected to mRNA
isolation with TRIzol (Invirogen). The isolated mRNAs were
treated with DNase I (Invitrogen) before reverse transcription
using a SuperScript kit (Invitrogen). TaqMan real-time PCR
was used to quantify expression levels of Nkx2.5 using
commercially available primers (Mm01309813_S1 for Nkx2.5;
Applied Biosystems, Foster City, CA). Gapdh (Mm9999
9915_g1; Applied Biosystems) was included as an internal
control for normalization. The comparative Ct (2
 DDCT)
method was used for calculation.
13
Measurement of Heartbeat Rate
To measure embryonic heartbeat rate, we followed a previ-
ously established in vitro measurement protocol.
14 Brieﬂy,
embryos at E10.5 were dissected in prewarmed ADS buffer
containing glucose, and hearts were excised and cultured in
DMEM containing 10% FBS and 1% antibiotics at 37°C and
10% CO2 for 24 hours. Heartbeats were counted under
inverted microscope for 10 seconds 3 times for each heart.
Heartbeat counts were converted to heartbeat rate per
minute.
Chromatin Immunoprecipitation Assays and
Electrophoretic Mobility Shift Assay
For cell culture chromatin immunoprecipitation (ChIP) assay,
Flag-Shox2a and Nkx2.5-Luc constructs were cotransfected
into HL-1 cells. After 48 hours in culture, cells were incubated
with culture media containing 1% formaldehyde (37%) at 37°C
for 10 minutes, washed with Dulbecco’s PBS (DPBS), and
then scraped from culture dishes in DPBS containing a
complete protease inhibitor cocktail. Cells were pelleted by
centrifugation (2000 rpm, 4 minutes, 4°C), resuspended in
SDS lysis buffer (1% SDS, 10 mmol/L of EDTA, and
50 mmol/L of Tris [pH 8.1]), and sonicated to shear DNA to
lengths between 200 and 500 bps. After centrifugation (13
000 rpm, 10 minutes, 4°C), the sonicated lysate was diluted
in 10-fold ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100,
1.2 mmol/L of EDTA, 16.7 mmol/L of Tris [pH 8.1], and
167 mmol/L of NaCl), and then incubated with 60-lL washed
Dynal magnetic beads A+G (1:1) at 4°C overnight for
preclearing. Meanwhile, 60-lL Dynal magnetic beads A+G
(1:1) were washed and incubated with anti-Flag antibodies on
a rotary platform at 4°C overnight. After washing with
blocking solution (PBS with 0.5% BSA), the antibody/magnetic
beads were mixed with the precleared cell lysate and
incubated on a rotary platform at 4°C overnight. Samples
were then rinsed with wash buffer (50 mmol/L HEPES [pH
7.6], 100 mmol/L of LiCl, 1 mmol/L of EDTA, 1% NP-40, and
0.7% Na-deoxycholate) 6 times and once with TE buffer
containing 50 mmol/L of NaCl and collected by centrifuga-
tion (960g, 3 minutes, 4°C) to remove residual TE buffer.
DNA-protein complexes were eluted in elution buffer
(50 mmol/L of Tris [pH 8.1], 10 mmol/L of EDTA, and 1%
SDS) at 65°C for 15 minutes. The elute was collected by
centrifugation (16 000g, 1 minute, room temperature) and
incubated at 65°C overnight to reverse the cross-links.
Residual RNA was removed by RNase A (0.2 lg/mL) at 37°
C for 2 hours and proteins removed by proteinase K (0.2 mg/
mL) at 55°C for 30 minutes. Finally, the pull-down DNA was
extracted by phenol and coprecipitated with glycogen by
ethanol. Regular PCR was performed to analyze the ChIP
samples. The following 11 pairs of primers were used.
Forward1: 50-GCCAGACGAAGAGCAGAGTC-30
Reverse1: 50-ATTGGCGAGAAAGCAAACAG-30
Forward2: 50-GAGTTGCGATTCTTCCCAAA-30
Reverse2: 50-CAATCAGCCGCGAAAAGTAT-30
Forward3: 50-ATTCCGGGTGATAGTTGCAG-30
Reverse3: 50-AAGGGTTTTTGGCTCAACCT-30
Forward4: 50-AGCTACCCCGGAATTTGACT-30
Reverse4: 50-CTTTCCAACGTGGCTTCTGT-30
Forward5: 50-TTCCCAGCCATTGTAACACA-30
Reverse5: 50-CAGTGACTTTCCCACCCCTA-30
Forward6: 50-CCCAATATAGCTCCCCCAAT-30
Reverse6: 50-ACCCTCCCGAGATTGAAGAT-30
Forward7: 50-CTTTGGACTGCTTGGAGAGG-30
Reverse7: 50-TCCTTCCTGCTTTTCCTCAA-30
Forward8: 50-CCAGGAGGGACAGTTCACAC-30
Reverse8: 50-AGGCTAACCTCTGGGAGAGC-30
Forward9: 50-CTGGAATCGATGTGCCTTCT-30
Reverse9: 50-CTGCCTGGATTCTCCTGAAG-30
Forward10: 50-AGTCAATTCCCCAACAATGC-30
Reverse10: 50-TTGTTCTGGGACGAACACTG-30
Forward11: 50-TTCTGGCTTTCAATCCATCC-30
Reverse11: 50-CGCGACACATTTGGGATAGT-30
For small embryonic heart tissue ChIP assay, we followed a
previously published protocol,
15,16 with minor modiﬁcations.
In short, 4 to 5 freshly dissected hearts from E12.5 mouse
embryos were incubated with 300 lL of trypsin (2.5 mg/mL)
in TE at 37°C for 5 minutes and further disassociated with a
yellow-tip P-200. Cell culture media (700 lL) were added to
inactive the trypsin, and the mixture was incubated with
100 lL of crossing buffer (0.1 mol/L of NaCl, 1 mmol/L of
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HEDTA, 0.5 mmol/L of EGTA, 50 mmol/L of HEPES [pH 8.0],
and 11% formaldehyde) for 30 minutes at room temperature
with mild agitation on a platform shaker. The cross-linking
was stopped by adding 55 lL of 2.5 mol/L of glycine. After
incubation for 5 minutes on ice, pellet was collected by
centrifugation (5 minutes at 2000 rpm), rinsed with 1 mL of
ice-cold PBS, and suspended in 1 mL of lysis buffer
(50 mmol/L of HEPES [pH 8.0], 0.14 mol/L of NaCl,
1 mmol/L of EDTA, 10% glycerol, 0.3% NP-40, 0.15% Triton-
X 100, and fresh proteinase inhibitor) and placed on ice for
10 minutes before centrifugation (8 minutes at 2500 rpm).
Pellet was suspended in 1 mL of buffer 2 (0.2 mol/L of NaCl,
1 mmol/L of EDTA, 0.5 mmol/L of EGTA, 10 mmol/L of Tris
[pH 8.0], and proteinase inhibitor) and incubated at room
temperature for 10 minutes before being spun down (8 min-
utes at 2500 rpm) and resuspended in 2 mL of buffer 3
(1 mmol/L of EDTA, 0.5 mmol/L of EGTA, 10 mmol/L of Tris
[pH 8.0], and proteinase inhibitor). Sonication was applied to
the mixture to shear DNA-protein complex, which was then
diluted to a ﬁnal concentration of 0.5% with the appropriate
amount of fresh 20% Sarkosyl solution, and incubated at room
temperature for 10 minutes, followed by centrifugation
(13 000 rpm, 10 minutes). Approximately 500 lL of super-
natant was mixed with 150 lL of ChIP cocktail mix
(0.43 mol/L of NaCl, 0.43% sodium deoxycholate, and 4.3%
Triton-X 100) and pretreated magnetic beads/antibody mix-
ture were incubated on a rotary platform at 4°C for overnight.
The next steps followed that for cell culture ChIP assay as
described above. Regular PCR was performed to analyze the
ChIP samples by using the primer pair Forward6 and Reverse6
as described above.
For gel mobility shift assays, DNA probes were generated
by annealing the following 2 complementary oligonucleotides
that are 50 labeled with IRDye800CW:
Oligo6F-800: 50-/5IRD800/CCAATTAAACGGTAATATTTC-30
Oligo6R-800: 50-/5IRD800/GAAATATTACCGTTTAATTGG-30
Nuclear protein extracts from cultured cells 48 hours after
transfection were prepared by the use of Thermo Scientiﬁc
NE-PER Nuclear and Cytoplasmic Extraction Kit. Complete
Protease Inhibitor (Roche) and phosphatase inhibitor were
used at a concentration of 1 tablet per 25 mL of extraction
buffer.
The Odyssey
  electrophoretic mobility shift assay (EMSA)
buffer kit (Catalog No.: 829-07910; LI-COR Biosciences) was
used for gel shift reactions according to the manufacturer’s
instruction. Reaction mixtures were preincubated with IRDye
800CW-labeled probes at room temperature for 5 minutes
before the addition of nuclear extracts. Mixtures were
incubated at room temperature for 20 minutes before being
loaded on a native polyacrylamide gel. In competition
experiments, 10-, 50-, 75- and 100-fold excessive unlabeled
competitor DNA was included during preincubation. In
supershift experiments, the nuclear extracts were preincu-
bated with 1 lg of anti-HA antibody at room temperature for
15 minutes before mixing with probes. Images were revealed
on the Odyssey Infrared Imaging System.
Statistical Analysis
All data are expressed as mean standard deviation, and
statistical signiﬁcance is established at P<0.05. In Figure 4,
the luciferase activities of different Gal4-Shox2 constructs,
Shox2 and its mutants, and different treatment of the same
report constructs were measured. Each assay was performed
in triplicate and repeated twice. In Figure 5, the levels of
Nkx2.5 mRNA expression in the hearts from wild-type (WT)
(n=5), Shox2a-DM
CO (n=4), and Shox2a
CO (n=3) newborn mice
were determined by real-time reverse transcriptase (RT)-PCR.
In Figure 6, the beating rate of the isolated embryonic hearts
of WT (n=6), Shox2
CKO (n=4), Shox2
CKO, Shox2a-DM
CO (n=4),
and Shox2
CKO;Shox2a
CO (n=3) were measured. Comparison of
the different mean values was performed using Wilcoxon’s
rank-sum test.
Results
Shox2a Interacts With the B56d Regulatory
Subunit of PP2A
The Shox2 gene encodes 2 alternatively spliced isoforms:
Shox2a and a shorter version Shox2b.
7,9,17 Our previous
studies have identiﬁed the transcription activity of Shox2a and
Shox2b protein within the C-terminus, and both isoforms can
act as either a transcriptional activator or a repressor in a cell-
type–speciﬁc manner.
18 In order to reveal the functional
mechanisms of Shox2 protein, we set out to identify Shox2
interacting proteins by a yeast 2-hybrid screen. In order to
reduce false positives from yeast 2-hybrid screen, we used
Shox2a without the OAR (opt, aristaless, rax) domain (named
Shox2aT) as the bait to screen a cDNA library from E11.5
mouse embryo. Among those highest hit potential interacting
proteinsisthedisoform (Ppp2r5d)ofB56regulatorysubunitof
protein phosphatase 2A (PP2A). Further analysis showed that
the whole sequence of Shox2a, except the OAR domain, is
essential for interaction with PP2A (Figure 1A). However,
Shox2b failed to interact with PP2A. PP2A is a heterotrimeric
serine/threonine protein phosphatase composed of 2 highly
conserved subunits (the catalytic C subunit and the structural
A subunit) and a highly variable regulatory B subunit. Sequence
comparisons showed that the Shox2a-interacting clones
encompass all of the amino acid sequence of B56d, which
contains an A subunit-binding domain required for interaction
of B subunit with the PP2A A subunit. Coimmunoprecitpitation
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H(Co-IP) assays further conﬁrmed physical interaction of
Ppp2r5d with Shox2a, but not Shox2b (Figure 1B).
Shox2a Is Phosphorylated Exclusively on Ser92
and Ser110 In Vivo
The interaction between Shox2a and PP2A regulatory subunit
B56d suggests an involvement of protein phosphorylation on
Shox2a. To verify whether Shox2a is indeed phosphorylated,
we transfected HA-tagged Shox2a expression vector (CMV-
HA-Shox2a) into 293T cells and analyzed the expressed
proteins by Western blotting analysis, which revealed 2
slightly shifted forms of Shox2a (Figure 2A). Digestion of
immunoprecipitated proteins by lambda protein phosphatase
(k-PPase) eliminated the shifted forms, conﬁrming the
presence of phosphorylated Shox2a (p-Shox2a) (Figure 2A).
Based on these observations, we reasoned that Shox2a
contains 2 phosphorylation sites, with the slower migrating
form bearing a single-site phosphorylation, and the slowest
migrating one carrying phosphorylation on both sites.
Because no phosphorylation form of Shox2b was detected
by the similar analysis (data no shown), the phosphorylation
sites must reside within the N-terminal region that is missing
in Shox2b. Bioinformatic analysis revealed potential phos-
phorylation sites in this region (Table). We conducted a site-
directed mutagenesis assay on each of these potential sites
and identiﬁed Ser92 and Ser110 as the true phosphorylation
sites, as evidenced by the fact that either S92A or S110A
mutation (serine to alanine) eliminated 1 phosphorylated
form, and double mutation (S92A/S110A, referred as Shox2a-
DM) eliminated both shifted bands on Western blotting
(Figure 2B). Based on the prediction from different kinase-
speciﬁc phosphorylation site prediction tools and analysis of
the adjacent residues of Ser92 and Ser110, we reasoned that
Shox2a may be the substrate of Erk1/2 and/or Cdc2.
Western blotting analysis after in vitro kinase assay demon-
strated that Shox2a, Shox2a-S92A, and Shox2a-S110A were
all phosphorylated by Erk2, resulting in the disappearance of
the unphosphorylated form and the increased amounts of the
Z-Shox2a + - +               
Z-Shox2b                         - +                          -
Flag-Ppp2r5d                  - + +
A
B
Figure 1. Interaction of Shox2a with the d isoform (Ppp2r5d) of
B56 regulatory subunit of protein phosphatase 2A (PP2A).
A, Shox2a interacts with Ppp2r5d determined by yeast mating.
The whole sequence of Shox2a, except the 14-amino acid motif
(OAR) at the C-terminus, is essential for interaction with PP2A. B, Z-
protein pull-down demonstrates physical interaction of Shox2a, but
not Shox2b, with Ppp2r5d. OAR indicates opt, aristaless, rax.
Shox2a        Shox2a-S92A    Shox2a-S110A     Shox2a-DM
*
Shox2a        Shox2a + λ-PPase
B A
Shox2a              C Shox2a Shox2a D Shox2a-S92A       Shox2a-S92A Shox2a-S92A
E Shox2a-S110A       Shox2a-S110A Shox2a-S110A
Cdc2     - +                         -
Erk2      - - +
Cdc2          - +                              -
Erk2 - - +
Figure 2. Shox2a is phosphorylated on serine residues in vivo. A, Western blotting assay
shows the presence of shifted forms of Shox2a that are eliminated by incubation of Shox2a
proteins with lambda protein phosphatase (k-PPase). B, Serine to alanine mutation on Ser92
(Shox2a-S92A), Ser110 (Shox2a-S110A), or both sites (Shox2a-DM) eliminates phosphor-
ylated Shox2a forms. Treatment of immunoprecipitated Shox2a (C), Shox2a-S92A (D), or
Shox2a-110A (E) by Cdc2 or Erk2 demonstrates that Shox2a can be phosphorylated by
Erk2, but not Cdc2. Red arrows point to the unphosphorylated band and red start indicates
the disappearance of unphopshorylated band after Erk2 treatment in (C). Cdc2 indicates cell
division control protein 2; Erk1/2, extracellular signal-regulated kinase 1 and 2.
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these proteins were not phosphorylated by Cdc2. We
concluded that Shox2a is phosphorylated on serine residues
92 and 110 by Erk1/2.
To determine that Shox2a is indeed phosphorylated in the
developing SAN, we generated antibodies that recognize
phosphorylated Ser92 and Ser110 of Shox2a, respectively,
whose speciﬁcity was proved by Western blotting on Shox2a,
Shox2a-S92A, Shox2a-S110A, and Shox2a-S92A/S110A
(Shox2a-DM) proteins (data no shown). Both antibodies
detected the presence of p-Shox2a proteins in the mouse
developing SAN (Figure 3A through 3F), in an overlapping
pattern with Hcn4, the molecular marker of the SAN
(Figure 3C and 3G). Western blotting assay further conﬁrmed
the presence of p-Shox2a in the mouse embryonic heart
(Figure 3H). Furthermore, we also detected the presence of
p-SHOX2a in the human embryonic SAN (Figure 3D), sug-
gesting a conserved function of Shox2a in SAN development
in mice and humans.
Functional Signiﬁcance of Shox2a
Phosphorylation
We next sought to investigate the functional signiﬁcance of
Shox2a phosphorylation. Because protein phosphorylation
could change the conformation and hence the function of
protein, we ﬁrst examined whether phosphorylation would
modify the transcriptional activity of Shox2a. The transcrip-
tion activity assay of Gal4-Shox2a and its mutants demon-
strated that Shox2a and its phosphorylation mutants all
possessed transcriptional repressive potential in HEK-293T
cells (Figure 4A), suggesting that phosphorylation does not
change the transcription potential of Shox2a protein.
We reported previously that Shox2a acts as a transcrip-
tional repressor on Nkx2.5 in vitro and in vivo.
6,10 To
determine whether phosphorylation confers Shox2a-repres-
sive capability speciﬁcally on Nkx2.5, we carried out reporter
gene expression assays in the HL-1 cardiac muscle cell line
using the Nkx2.5-Luc reporter.
6 Cotransfection of the reporter
construct with Shox2a or its various mutant forms demon-
strated signiﬁcant changes in the repressive effect of Shox2a
phosphorylation mutants on Nkx2.5 promoter activity (Fig-
ure 4B). As compared to Shox2a, both Shox2a-S92A and
Shox2a-S110A exhibited signiﬁcantly compromised repressive
activities on the Nkx2.5 promoter, and Shox2a-DM even lost
its repressive activity completely. Consistent with these
observations, treatment of Shox2a-transfected cells with
PP2A-speciﬁc inhibitor, okadaic acid, increased the transcrip-
tional repressive activity of Shox2a in a dose-dependent
manner (Figure 4C), and conversely, addition of the highly
selective Erk1/2 inhibitor, U0126, to cell culture led to a
dose-dependent loss of repressive activity of Shox2a (Fig-
ure 4D). All together, these observations indicate a require-
ment of phosphorylation on both sites for Shox2a to achieve
its maximal repressive activity on the Nkx2.5 promoter in cell
cultures.
We have reported previously that overexpression of Shox2a
in the developing mouse heart results in a reduction of Nkx2.5
expression and abnormal cardiac formation.
10 To determine
whether or not Shox2a phosphorylation is also required for its
activity in vivo, we generated a conditional Shox2a-S92A/
S110A Tg allele (pMes-Shox2a-DM
CO). Tissue-speciﬁc overex-
pression of transgenes in the developing mouse heart was
achieved by crossing pMes-Shox2a-DM
CO Tg mice or pMes-
Shox2a
CO line to the cTnt-Cre Tg line,
19 respectively. Similar
to the previous report,
10 examination of the cTnt-Cre;pMes-
Shox2a
CO Tg heart (referred to as Shox2a
CO) at newborn (P0)
revealed a signiﬁcantly round-shaped heart and an overall
Table. Shox2a Phosphorylation Site Prediction
Pos Context Score Pred
24 KEAITYREV 0.963 *T*
52 DDRSSPAVR 0.991 *S*
92 GGGRSPVRE 0.900 *S*
105 AAERSREPG 0.939 *S*
110 REPGSPRLT 0.996 *S*
114 SPRLTEVSP 0.942 *T*
117 LTEVSPELK 0.984 *S*
143 KQRRSRTNF 0.995 *S*
D B A
Anti-S92P Anti-S92P Anti-S110P Anti-Hcn4
C
E F
E11.5 E11.5 Human week 7
H G
E11.5
/
E13.5 E13.5 E13.5
S92P/S110P
S92P
Figure 3. Presence of p-Shox2a in the SAN of mouse and
human embryos. Immunohistochemical staining using anti-S92P
(A, E) or anti-S110P (B, F) speciﬁc antibodies demonstrates the
presence of p-Shox2a in the SAN of E11.5 (A, B) and E13.5 (E, F)
mouse embryo. Immunohistochemical staining shows the expres-
sion of Hcn4 in the SAN of E11.5 (C) and E13.5 (G) mouse
embryo. D, Immunohistochemical staining using anti-S92P anti-
body reveals the presence of p-SHOX2a in the SAN of human
embryo at 7-week gestation. F, Western blotting using anti-S92P
antibody reveals the presence of p-Shox2a in E11.5 mouse
embryonic hearts. Red arrows point to the SAN region. Scale
bar=20 lm for all panels. SAN indicates sinoatrial node.
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staining, when compared to WT littermate controls (Figure 5A
through 5F). In contrast, no obvious difference was observed
in the cTnt-Cre;pMes-Shox2a-DM
CO) Tg heart (referred to as
Shox2a-DM
CO), as compared to controls, in terms of heart
morphology and overall Nkx2.5 protein expression (Figure 5G
through 5I). Quantitative real-time RT-PCR assays further
conﬁrmed complete loss of repressive activity of Shox2a-DM
on Nkx2.5 mRNA expression in vivo (Figure 5J), consistent
with the results from in vitro reporter assays in cell cultures
(Figure 4).
It was demonstrated previously that Nkx2.5 activity is
detrimental to the normal development and function of the
early developing SAN and that Shox2 shields SAN cell fate by
repressing Nkx2.5 expression.
4,6,10 To further conﬁrm the
requirement of phosphorylation for Shox2a to repress Nkx2.5
expression in the developing SAN, we conducted rescue
experiments by activating the Shox2a
CO or Shox2a-DM
CO Tg
allele in the heart of mice carrying cTnt-Cre and Shox2
F/F
alleles.
20 Whereas mice bearing cTnt-Cre;Shox2a
CO;Shox2
F/F
compound alleles could survive to birth and exhibited
inhibition of Nkx2.5 expression in the SAN, cTnt-Cre;Shox2a-
DM
CO;Shox2
F/F mice showed cardiac phenotypes resembling
that noted in cTnt-Cre;Shox2
F/F(referred to as Shox2
CKO)
mice, including ectopic activation of Nkx2.5 in the SAN and
embryonic lethality between E11.5 and E12.5 (Figure 6A, 6B,
6D through 6G). In vitro heartbeat rate measurement showed
near normal beat rate of embryonic hearts from cTnt-Cre;
Shox2a
CO;Shox2
F/F mice and signiﬁcantly reduced beat rates
of embryonic hearts from both cTnt-Cre;Shox2
F/F and cTnt-
Cre;Shox2a-DM
CO;Shox2
F/F mice, as compared to WT controls
(Figure 6C). We recognize that this in vitro heartbeat rate
measurement does not reﬂect real in vivo embryonic heart-
beats and could present large variations. However, the direct
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Figure 4. Shox2a phosphorylation is required for its speciﬁc repressive effect on the
Nkx2.5 promoter. A, Luciferase assays show that Shox2a and its mutants have similar
transcriptional repressive potential when fused with Gal4 DNA-binding domain. B, Mutations
on the phosphorylation sites compromise Shox2a’s repressive effect on the Nkx2.5
promoter activity. C and D, Treatment of transfected cells with the PP2A inhibitor, okadaic
acid, leads to a dose-dependent increase in Shox2a’s repressive function on the Nkx2.5
promoter, whereas treatment with the Erk1/2 inhibitor, U0126, results in a dose-dependent
loss of the repressive activity of Shox2a on the Nkx2.5 promoter. *P<0.05. PP2A indicates
protein phosphatase 2A.
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Hcomparison under the same condition indeed revealed a
signiﬁcant difference in beat rates between mice with
different genotype. Nevertheless, these results indicate the
in vivo functional importance of Shox2a phosphorylation
during SAN development.
Phosphorylation of Shox2a Is Necessary for Its
Binding to the Nkx2.5 Promoter
It has been well established that post-translational modiﬁca-
tions, including phosphorylation of transcription factors,
J
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n *
p≤ 0.1143
0.4
0.8
t
i
v
e
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x
2
.
5
e
x
p
0
R
e
l
a
t
Wild type Shox2aCO Shox2a-DMCO
Figure 5. Transgenic expression of Shox2a, but not Shox2a-DM, mutant in mouse heart
results in down-regulation of Nkx2.5 and cardiac malformation. A P0 control mouse heart
shows its gross morphology (A), absent EGFP expression (B), and immunostaining of Nkx2.5
(C). A P0 cTnt-Cre;pMes-Shox2a (Shox2a
CO) mouse heart exhibits gross blunt heart apex (D),
EGFP expression (E), and reduced level of Nkx2.5 protein (F). A P0 cTnt-Cre;pMes-Shox2a-
DM (Shox2a-DM
CO) shows similar gross morphology (G) and unaltered Nkx2.5 expression
(I), as compared to controls. Transgene expression is revealed by EGFP expression under
UV light (H). J, Real-time RT-PCR assays show transcriptional reduction of Nkx2.5
expression in the heart from Shox2a
CO transgenic mice at P0 (n=3). In contrast, the level of
Nkx2.5 mRNA expression in the heart from Shox2a-DM
CO transgenic mice (n=4) remains
the same as control (n=5). *P<0.05. Scale bars in red represent 1 mm and scale bars in
black represent 100 lm. EGFP indicates enhanced green ﬂuorescent protein; PCR,
polymerase chain reaction; WT, wild type.
DOI: 10.1161/JAHA.114.000796 Journal of the American Heart Association 9
Shox2 Phosphorylation in SAN Development Liu et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
Hregulate protein function at different levels, such as subcel-
lular localization, dimerization, protein-protein interactions,
and DNA binding. To investigate the underlying mechanisms
of how phosphorylation alters Shox2a transcriptional potential
on Nkx2.5 expression, we conducted a series of experiments.
ICC revealed exclusive nuclear localization of both Shox2a
and Shox2a-DM in cell cultures (Figure 7A), indicating that
nuclear localization of Shox2a is not dependent on its
phosphorylation. Because many homeodomain proteins form
homodimers to exert their functions, and Shox2a was found
to form homodimer as well,
4 we tested whether phosphory-
lation is required for Shox2a dimerization by generating Z-tag-
Shox2a, Myc-Shox2a, Z-tag-Shox2a-DM, and Myc-Shox2a-DM
constructs and transfecting these constructs into HEK-293T
cells, followed by Co-IP and Western blotting assays. The
results showed that, similar to Shox2a, Shox2a-DM is able to
form homodimer, indicating that phosphorylation has no
effect on dimerization of Shox2a protein. Because the
replacement of S92 and Ser110 with Ala did not alter the
transcriptional potential of Shox2a protein, but caused
dramatic loss of its repressive activity, speciﬁcally on the
Nkx2.5 promoter (Figure 4), we reasoned that Shox2a phos-
phorylation is likely related to its speciﬁc binding to the
Nkx2.5 promoter. In order to test the hypothesis, Flag-Shox2a
and the Nkx2.5-Luc reporter constructs were cotransfected
into HL-1 cells, and the nuclear extract was subject to ChIP
PCR analysis. Eleven pairs of primers were designed to evenly
cover the 3.3-kb promoter region and 2 Shox2a-binding
fragments were identiﬁed from PCR analysis of the ChIP
samples (Figure 8A and 8B). These 2 sites (site-1:  2937 to
 2727; site-2:  2160 to  1814) both contain the SHOX
AATT-palindromic binding sequence. Bioinformatic search
indicates that these 2 sequences are highly conserved across
the species, including the human, rat, dog, and mouse (data
not shown). Interestingly, they are the only 2 regions that are
highly conserved between the human and mouse within the
3.3-kb Nkx2.5 promoter region. Because the site-2 contains a
very typical SHOX-binding sequence (ATTAAACGGTAAT), we
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Figure 6. Rescue of embryonic lethality and cardiac defects of Shox2 conditional mutant
by transgenic expression of Shox2a, but not Shox2a-DM. Panoramic comparison between
littermates of wild-type (A) and cTnt-Cre;Shox
F/F;pMes-Shox2a (Shox2
CKO;Shox2a
CO) mice
(B) at P0. C, Heartbeat rate measurement shows signiﬁcantly reduced heartbeat rate in
Shox2
CKO (50 14.1 bpm) and cTnt-Cre;Shox2
F/F;pMes-Shox2a-DM (Shox2
CKO;Shox2a-
DM
CO) (51 7.4 bpm) embryos, which was less than 40% of that in wild-type controls
(134 8.3 bpm). However, Shox2
CKO;Shox2a
CO hearts exhibit a heartbeat rate
(102 14 bpm) comparable to controls. Immunohistochemical staining shows lack of
Nkx2.5 expression in an E11.5 control SAN (D), ectopic Nkx2.5 expression in an E11.5
Shox2
CKO embryo (E), and rescue of ectopic Nkx2.5 expression in the SAN of Shox2
CKO
embryos by transgenic expression of Shox2a (F), but not Shox2a-DM (G). Arrows point to
the SAN region. *P<0.05. Scale bar=50 lm. SAN indicates sinoatrial node.
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embryonic heart chromatin and subsequent EMSA studies.
We took advantage of a recently created Flag-HA-Shox2a
knock-in allele (to be reported elsewhere) in the lab and
collected hearts from E12.5 embryos for ChIP assay. The
results conﬁrmed the site-2 of the Nkx2.5 promoter as a
genome-speciﬁc element recognized by Shox2a in vivo
(Figure 8C). To further conﬁrm direct binding and the
Shox2a-binding sequence, EMSA was performed by using a
60-bp probe that covers the AATT-palindromic sequence in
the site-2 of the Nkx2.5 promoter. Incubation of labeled
probes with the nuclear extracts of HA-Shox2a transfected
cells, but not the nuclear extracts of control cells and HA-
Shox2a-DM transfected cells, gave rise to 2 shifted bands,
most likely presenting binding of Shox2a monomers and
dimers to the probes (Figure 8D). The binding speciﬁcity was
conﬁrmed by competitive EMSA with excessive cold probes
(Figure 8D), as well as by supershift assay with anti-HA
antibodies (Figure 8E). These results demonstrate that
Shox2a binds to the Nkx2.5 promoter directly and that
phosphorylation of Shox2a is required for such binding to
exert its transcriptional activity.
Discussion
Cardiac transcription factors, such as Nkx2.5, the GATA family
members, and myocyte enhancer factor 2, play essential roles
in embryonic heart development and postnatal heart func-
tions. Among them, Nkx2.5 is a central regulator.
21 In
mammals, Nkx2.5 is expressed in the developing heart,
including the ﬁrst and second heart ﬁelds, and is crucial for
heart patterning and development.
22 Though Nkx2.5 is
expressed in cardiomyocytes throughout the whole heart, it
is absent in the myocardium of the sinus horns and the SAN
during early development.
4,10,23 Mutation in Shox2 leads to
ectopic Nkx2.5 expression in the developing SAN and disrupts
the expression of the SAN genetic regulatory genes, leading
to deviation of the fate of SAN cells.
6,7 This phenotype was
recapitulated in mice carrying Tg expression of Nkx2.5 to the
SAN,
10 indicating that Nkx2.5 activity is detrimental to the
A Shox2a Shox2a-DM
Anti-HA Ab
DAPI
Input
Myc-Shox2a
Input
Myc-Shox2aDM
Z-Shox2a
Z Shox2aDM
+
+
-
B
Z-Shox2aDM
Myc-Shox2a
Myc-Shox2aDM
+
+
+
-
-
-
Anti-Myc
Figure 7. Abolishment of the phosphorylation sites in Shox2a does not alter its nuclear
localization (A) and dimerization (B). Scale bar=15 lm..
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essential role in regulating SAN development and function
through the repression of Nkx2.5 expression. However, the
mechanism underlying the repression of Nkx2.5 by Shox2
remained unknown. In the present study, we demonstrate the
direct binding of Shox2a to the Nkx2.5 promoter. We
identiﬁed 2 Shox2a-binding sites within the 3.3-kb mouse
Nkx2.5 promoter region. Both sites contain the SHOX AATT-
palindromic consensus binding sequences and are highly
conserved across the species. Two cardiac enhancers,
referred to as activating region (AR) 1 and AR2, have been
identiﬁed previously in the 50-ﬂanking region of the mouse
Nkx2.5 gene by serial deletion experiments.
22,24 AR2 is
located between  3 and  2.5 kb upstream of the gene and
contains evolutionarily conserved binding sites for Smad,
GATA, and NFAT, the key regulators of Nkx2.5 expression.
25,26
This enhancer is repressed by a closely adjacent inhibitory
sequence element, named inhibitory region (IR) 2. It has been
shown that the cardiac activity of AR2 is inhibited when the
IR2 is activated.
22,24 Interestingly, the Shox2a binding site-1
identiﬁed in this study overlaps with AR2 and the site-2 is
located within IR2. Although additional Shox2a-binding sites
very likely exist in the Nkx2.5 regulatory elements, binding of
Shox2a to the site-2 within IR2 appears to contribute to the
repression of Nkx2.5.
The homeodomain-containing transcription factors play
crucial roles during embryonic development by regulating
pattern formation and organogenesis.
27,28 Protein phosphor-
ylation represents a major molecular mechanism to regulate
various functions of proteins in vivo.
11 Phosphorylation is
found to regulate the transcriptional activity of many homeod-
omain proteins during embryogenesis. For example, phosphor-
ylation modulates the biological activities of human SHOX,
12
another member of the SHOX family that has been shown to
have a similar function as Shox2 in the regulation of SAN
development and pacemaking function, in addition to several
input
IgG
control
Flag 
control
Flag-
Shox2a 
CHIP input
IgG
control
Flag 
control
Flag-
Shox2a 
CHIP
A B
C
D E
HA-Shox2a --++++ + + + ++
HA-Shox2a-DM - +
Homologous 
competitor
Heterologous 
competitor
-
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IgG
control
Flag 
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Flag-
Shox2a 
CHIP
- ++
-- -
- - + Anti-HA Ab
Figure 8. Binding of Shox2a to the Nkx2.5 regulatory elements depends on its
phosphorylation. ChIP assays reveal 2 Shox2a-binding elements, site-1 (A) and site-2 (B),
within the 3.3-kb Nkx2.5 promoter region. (C) ChIP assays using mouse embryonic
hearts conﬁrm binding of Shox2a to the site-2 in vivo. D, Electrophoretic mobility shift
assay (EMSA) reveals speciﬁc binding of the site-2 sequence by nuclear extracts from
cells expressing HA-Shox2a, but not HA-Shox2a-DM. Red arrows point to the shift
bands. (E) Supershift assay with anti-HA antibodies demonstrates speciﬁc DNA with
HA-Shox2a. Green arrow points to the supershifted band. ChIP indicates chromatin
immunoprecipitation.
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8 In the current study, we present evidence that
Shox2a interacts with the d isoform of the B56 regulatory
subunitofPP2AandisphosphorylatedonSer92andSer110by
Erk1/2 in vitro and in vivo. The presence of p-Shox2a in the
developing SAN of mouse and human embryos suggests a
conserved biological function during SAN development in both
humans and mice. Indeed, the failure of the Shox2a-DM
transgene to rescue ectopic Nkx2.5 expression in the SAN as
well as bradycardia in Shox2 mutant embryos further supports
the functional importance of Shox2a phosphorylation. A recent
study using systemic mass spectrometry also revealed the
presence of p-Shox2a (phosphorylation on Ser110) in the adult
mouse brain,
29 suggesting a conserved regulatory mechanism
of Shox2a function by phosphorylation in other organs.
In contrast to their wide spectrum of biological functions of
homeodomain transcription factors in vivo, the homeodomain
itself is highly conserved and in vitro DNA-binding studies
have revealed binding of most homeodomain proteins to a
similar short consensus DNA sequence containing the TAAT
motif.
28,30 This apparent discrepancy indicates that target
gene speciﬁcity of each homeodomain protein in vivo may not
depend on the homeodomain only, but may be achieved by a
complex combination of different elements, such as speciﬁc
expression patterns, interactions with different cofactors,
31
differential DNA-binding afﬁnities to individual target sites,
32
or post-translational modiﬁcations.
33 Our present studies
demonstrate that the phosphorylation of Shox2a is not
necessary for its nuclear localization and dimerization, but is
essential for its speciﬁc binding to the Nkx2.5 promoter.
Mutations on the phosphorylation sites of Shox2a compro-
mise its capability to repress Nkx2.5 expression both in cell
culture and in the developing heart. Nevertheless, our studies
reveal a post-translational modiﬁcation mechanism of biolog-
ical function of Shox2a and demonstrate that phosphorylation
is essential for Shox2a to repress Nkx2.5 during SAN
development and differentiation.
Clinical Perspective
Although no known human syndrome has been mapped or
linked to the SHOX2 locus, studies using mouse gene-
targeting models have demonstrated an essential role for
Shox2 in limb skeletogenesis, palatogenesis, temporoman-
dibular joint formation, and CV development.
4 Human SHOX2
is located on chromosome 3q25-q26, a chromosomal region
that has been implicated in Cornelia de Lange syndrome,
which is characterized by growth and mental retardation, cleft
palate, abnormally situated eyelids, nose and ear deformities,
as well as heart and limb defects. The expression patterns of
mouse Shox2 are in perfect agreement with the features
noted in Cornelia de Lange syndrome. Thus, human SHOX2 is
a candidate gene for Cornelia de Lange syndrome. In addition
to its pivotal roles during embryogenesis, SHOX2 DNA
methylation has been used as a standard biomarker for
diagnosis of lung cancer in clinics.
34,35 In addition, it was
found recently that Shox2 plays a crucial role in determining
adipose distribution in mice and humans.
36 In a mouse model
in which Shox2 was replaced with a human SHOXa hypomor-
phic allele, despite formation of a morphologically normal SAN
and rescue of embryonic lethality, the mice developed
bradycardia and arrhythmia, suggesting a dose requirement
not only for SAN development, but also for its function.
8 Given
the fact that mouse Shox2 shares 99% identity with its human
counterpart at the amino acid level and both exhibit similar
expression patterns during embryonic development, including
the SAN, SHOX2 could represent a candidate gene for
mutation in human bradycardia and arrhythmia. The presence
of phosphorylated SHOX2a in the SAN of human embryos
would also predict an essential biological function for SHOX2a
phosphorylation in SAN development and its pacemaking
function.
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